Our products help improve medical care for people with chronic diseases globally.

We want to serve the largest possible number of medical indications in order to make the lives of those affected easier. Thus, not only our company, but also society benefits from our growth strategy. This is because products for self-medication and services for improving the success of therapy optimise the therapies of chronically ill people and thus significantly relieve the burden on the healthcare system. Our ambition is to enable people to access self-medication and medical care. We are also pursuing this ambition through through growth, which enables us to reach more people with our injection and infusion systems for safe and easy self-medication. Because self-medication fundamentally facilitates and improves the possibilities of medical care. The formulation of innovative medicines for subcutaneous injection, instead of intravenous infusion, enables self-treatment for more and more indications. And the use of generic versions of expensive original preparations or so-called biosimilars makes therapy more affordable and thus accessible to a larger group of patients.

Our contribution

  • Establishing as a global provider of self-medication
  • Access to innovative medicines and biosimilars
  • Improving patients’ quality of life

Sustainable development goals (SDGs)

Gesundheit und Wohlergehen Menschenwürdige Arbeit und Wirtschaftswachstum Industrie, Innovation und Infrastruktur

Highlights 2022/23

  • We have reached 400 000 more people with our Ypsomed products
  • We have provided access to six additional Biosimilars as a contribution to affordable medical care
  • We serve oncology as a new therapy area
  • We have concluded a further 35 new projects orders in the pen business for important disease areas

Learn more about our Access and Expansion ambitions in the annual report (PDF).

Latest news

Burgdorf – Ypsomed (SIX: YPSN) is building a new production hall in Schwerin and creating 60 new jobs in the process. The company held the groundbreaking ceremony last Friday thus signaling the start of the construction for the 3300 square meters of additional production space, plus a further 1600 square meters for warehouse capacity and logistics. Digging work is scheduled to begin in June. The plant is expected to be operational following a construction phase of one year. The expansion will allow Ypsomed's site in Schwerin to produce more than 250 million infusion sets, pens and autoinjectors per year going forward.